|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | A61K 9/16 | (2006.01) |
| A61K 31/4545 | (2006.01) | ||
| A61P 7/02 | (2006.01) |
| (11) | Number of the document | 3781132 |
| (13) | Kind of document | T |
| (96) | European patent application number | 19722333.2 |
| Date of filing the European patent application | 2019-04-15 | |
| (97) | Date of publication of the European application | 2021-02-24 |
| (45) | Date of publication and mention of the grant of the patent | 2024-03-20 |
| (46) | Date of publication of the claims translation | 2024-04-25 |
| (86) | Number | PCT/US2019/027456 |
| Date | 2019-04-15 |
| (87) | Number | WO 2019/204193 |
| Date | 2019-10-24 |
| (30) | Number | Date | Country code |
| 201862658175 P | 2018-04-16 | US |
| (72) |
BADAWY, Sherif, Ibrahim, Farag , US
STEVENS, Timothy, D. , US
KUNTZ, Daniel , US
WAYBRANT, Brett , US
|
| (73) |
Bristol-Myers Squibb Company ,
Route 206 & Province Line Road, Princeton, NJ 08543,
US
Pfizer Inc. , 66 Hudson Boulevard East, New York, NY 10001-2192, US |
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Apiksabano vaisto formos |
| APIXABAN FORMULATIONS |
| Payment date | Validity (years) | Amount | |
| 2026-03-03 | 8 | 185.00 EUR |
| 2027-04-15 |